 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Lung Cancer
Cancers that begin in the lungs are divided into two major types, non-small cell lung cancer and small cell lung cancer, depending on how the cells look under a microscope. Non-small cell lung cancer is more common than small cell lung cancer, and it generally grows and spreads more slowly. Small cell lung cancer, sometimes called oat cell cancer, is less common, grows more quickly and is more likely to spread to other organs in the body. [Source: www.nihseniorhealth.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Brain Metastases from Lung Cancer Study CEPO906A2227
Novartis Oncology is conducting a clinical research study to find out if the study drug, patupilone, is an effective and safe treatment for people who are 18 years or older and have non-small cell lung cancer that has spread to the brain, and that is recurrent in the brain after treatment. The research study is an open-label study, which means that everyone participating in the study will receive the study drug patupilone once every 3 weeks. Patupilone is given by intravenous infusion (directly into a vein) lasting approximately 20 minutes. Patients may remain in the study as long as they and the study doctor think it is in their best interest to participate. The study drug, patupilone, is an investigational drug which has not been approved by the FDA (US Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of people with your medical condition.
Trial phase: Phase 2 Participation Duration: Study site visits approx. 2 times a month. The first visits at cycles 1 and 3 may require overnight stays. A final study visit must be performed 28 days after last administration of study drug for all patients regardless of reason for discontinuation. Protocol Number: CEPO906A2227 Advanced Non-small Cell Lung Cancer Study CASA404A2301
The purpose of this study is to determine if adding the study drug ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with newly diagnosed advanced non-small cell lung cancer. The standard chemotherapy regimen that all patients receive in this study is paclitaxel plus carboplatin. Participants will also receive either ASA404 or a placebo (half will receive ASA404, half will receive placebo). The study drug ASA404 is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: Participants will receive a maximum of 6 cycles of study treatment. Each treatment cycle is 21 days (3 weeks) long. Participants will return to their doctor’s office every 3 weeks so that their condition can be monitored. The number of treatment cycles for each participant depends on how they respond to treatment and whether they suffer from any side effects. Protocol Number: CASA404A2301
Lung Cancer Study CASA404A2302
The purpose of this study is to determine if adding the investigational drug ASA404 to docetaxel (Taxotere®) makes the cancer treatment more effective in participants with advanced non-small cell lung cancer. The investigational drug, ASA404, is a medicine that has not been approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: This study is anticipated to last approximately 27 months. If the participant meets all the requirements to participate in the study, they will be randomly assigned into 1 of 2 possible groups: Group 1 will receive investigational drug ASA404 plus docetaxel, while Group 2 will receive a placebo (a dummy substance that has no effect on your body) plus docetaxel. Participants will be required to visit the study center to receive a treatment and/or evaluation every 3 weeks. Protocol Number: CASA404A2302 |
